Vectus Biosystems Valuation

Is VBS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VBS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VBS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VBS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VBS?

Key metric: As VBS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VBS. This is calculated by dividing VBS's market cap by their current revenue.
What is VBS's PS Ratio?
PS Ratio	3.7x
Sales	AU$1.14m
Market Cap	AU$4.26m

VBS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.1x
Enterprise Value/EBITDA	-1.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does VBS's PS Ratio compare to its peers?

The above table shows the PS ratio for VBS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5x
EX1 Exopharm	1.4x	n/a	AU$4.8m
NC6 Nanollose	9.6x	n/a	AU$2.9m
PAB Patrys	6.6x	n/a	AU$9.3m
NSB NeuroScientific Biopharmaceuticals	2.4x	n/a	AU$5.4m
VBS Vectus Biosystems	3.7x	n/a	AU$4.3m

Price-To-Sales vs Peers: VBS is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (5x).

Price to Sales Ratio vs Industry

How does VBS's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	10.0x	8.3%
VBS Vectus Biosystems	3.7x	n/a	US$2.77m
ARX Aroa Biosurgery	3.6x	20.1%	US$146.81m
IMC Immuron	3.5x	59.7%	US$11.17m

8 Companies		Estimated Growth	Market Cap
Industry Avg.	10.0x	15.3%
VBS Vectus Biosystems	3.7x	n/a	US$2.77m

No more companies

Price-To-Sales vs Industry: VBS is good value based on its Price-To-Sales Ratio (3.7x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is VBS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VBS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate VBS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.36

-26.0%

-17.0%

AVITA Medical

US$349.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.93

2.3%

20.4%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

-5.6%

-46.8%